Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage biopharmaceutical company focused on creating innovative therapies for oncology and rare diseases, targeting significant unmet medical needs. Utilizing its proprietary drug delivery technology, Conduit aims to improve the efficacy and safety of existing treatments, thereby enhancing patient outcomes and reducing adverse effects. Supported by a seasoned management team and strategic collaborations, the company is well-positioned to advance its pipeline of transformative products, with the potential to significantly influence the healthcare landscape.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-22.83M |
| Operating Margin | 0.00% |
| Return on Equity | -69.70% |
| Return on Assets | -23.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4084.02 |
| Price-to-Book | 0.02 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -55.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.12M |
| Float | 21,020 |
| % Insiders | 33.93% |
| % Institutions | 0.06% |
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 14, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding intellectual property covering novel solid forms of a major, first-in-class respiratory medicine, an asset class addressing a treatment market estimated at more than $20 billion annually.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a SAFE note with Pep'd Inc. (“Pep'd”), a US-based peptide company, expanding CDT's exposure to the growing US peptide market (the “Transaction”).
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that it has entered into a strategic transaction to increase its equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors, to 22.7% through the issuance of pre-funded warrants to purchase up to 12,131,770 shares of the Company's common stock, subject to shareholder approval at the Company's annual meeting of stockholders on August 28, 2026 (the “Transaction”).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDT and any ticker you trade — then tracks every position and per-strategy win rate.
